Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen, Sandoz Ask Federal Circuit For En Banc Review Of Zarxio Case

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen argues that a biosimilar applicant's ability to file an infringement suit does not make the statutory requirement to provide information to the BLA sponsor optional; Sandoz says statute does not provide BLA sponsor extra six months of exclusivity.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register